Track topics on Twitter Track topics that are important to you
(Reuters) - Staff reviewers for the U.S. Food and Drug Administration noted on Monday that there was a trend of increased death with Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab compared with placebo.
Original Article: J&J arthritis drug sirukumab raises safety concerns: FDA staffNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...